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ABSTRACT 
Antigen specific immunotherapy aims to tolerise patients to specific autoantigens 
that are responsible for the pathology of an autoimmune disease. Immune 
tolerance is generated in conditions where the immune response is supressed and 
thus gold nanoparticles (AuNPs) are an attractive drug delivery platform due to 
their anti-inflammatory effects and their potential to facilitate temporal and spatial 
delivery of a peptide autoantigen in conjunction with pro-tolerogenic elements. In 
this study we have covalently attached an autoantigen, currently under clinical 
evaluation for the treatment of type 1 diabetes (PIC19-A3 peptide), to AuNPs to 
create nanoscale (<5nm), negatively charged (-40 to -60mV) AuNP-peptide 
complexes for immunotherapy. We also employ a clinically approved microneedle 
delivery system, MicronJet600, to facilitate minimally-invasive intradermal delivery 
of the nanoparticle constructs to target skin-resident antigen presenting cells, 
which are known to be apposite target cells for immunotherapy. The AuNP-peptide 
complexes remain physically stable upon extrusion through microneedles and 
when delivered into ex vivo human skin they are able to diffuse rapidly and widely 
throughout the dermis (their site of deposition) and, perhaps more surprisingly, the 
overlying epidermal layer. Intracellular uptake was extensive, with Langerhans 
cells proving to be the most efficient cells at internalising the AuNP-peptide 
complex (94% of the local population within the treated region of skin). In vitro 
studies showed that uptake of the AuNP-peptide complexes by dendritic cells 
reduced the capacity of these cells to activate naïve T cells. This indicator of 
biological functionality encourages further development of the AuNP-peptide 
formulation, which is now being evaluated in clinical trials. 
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1. INTRODUCTION 
 
Antigen specific immunotherapy (ASI) uses autoantigen molecules or peptide 
epitopes thereof to promote immune tolerance in individuals with antigen specific 
autoimmune conditions e.g. Type 1 diabetes (T1D). This therapeutic approach 
attempts to address the immunological aetiology of an autoimmune disease rather 
than provide replacement treatment and this has a raft of potential clinical benefits. 
However, there is a delicate balance between homeostatic immune tolerance 
mechanisms to self-peptide and the inflammatory immune response to a foreign 
antigen. Moderation of this balance in vivo is a significant challenge and whilst ASI 
has been successful in animal models, translation to humans has proved 
challenging(von Herrath et al., 2013). Selection of the peptide autoantigen, its 
formulation and the route of delivery are all recognised as key parameters that 
need to be better understood and optimised to facilitate future clinical success 
(Hirsch and Ponda, 2015). 
In this study we selected the HLA-DR4 (DRB1*0401) restricted proinsulin peptide 
PIC19-A3 as a potential immunomodulatory treatment to delay, or even prevent, the 
onset of T1D. This peptide is associated with positive safety data in phase 1 clinical 
trials and is thought to function by modulating autoreactive CD4 T-cells (Thrower 
et al., 2009), thus preserving beta-cell function (Alhadj Ali et al., 2017). Our 
ambition is to use this peptide in conjunction with an immunomodulating element 
that could induce a local tolerogenic environment that directs the immune response 
towards regulation rather than inflammation. However, to achieve this ambition a 
drug delivery platform is required that can facilitate concomitant delivery of multiple 
therapeutic cargos and control the localised kinetics to ensure an appropriate 
bystander effect. This study has therefore used ultra-small (5nm) carbohydrate-
coated gold nanoparticles (AuNPs) with a high surface area-to-volume ratio (thus 
making them particularly suitable for the dense loading of therapeutic cargos (Love 
et al., 2005)), a multi-valent surface structure (for covalent or non-covalent 
conjugation to the surface (Ghosh et al., 2008; Kim et al., 2010; Rana et al., 2012)) 
and a tightly controlled dispersity to provide a platform for PIC19-A3 delivery. In 
tolerogenic approaches the aim is to minimise immune stimulation and promote a 
regulatory response and therefore we hypothesise that exploiting a AuNP platform 
with known anti-inflammatory properties (de Araujo et al., 2017) and clinical 
potential (Rana et al., 2012) may also be beneficial. 
Whilst AuNPs may provide an appropriate multi cargo delivery platform, it is also 
important to consider how to target this delivery vehicle to the target cells. The skin 
is rich in antigen presenting cells (APCs) and therefore has been extensively 
exploited as a dose-sparing route for conventional vaccination (Henri et al., 2010; 
Merad et al., 2008). However the APCs in this organ, the dendritic cells (DCs) and 
particularly Langerhans Cells (LCs), also have pivotal roles in immune regulation 
and tolerance (Mutyambizi et al., 2009). Whilst delivery of our AuNP peptide 
construct to the skin could take advantage of the immune regulatory functions of 
these APCs, it will be important to minimise the inflammation that is caused when 
the outermost skin barrier, the stratum corneum, is breached. Microneedles (MNs) 
therefore provide an appropriate means of delivery. MNs are ultra-short needles 
that have previously been used for dose-sparing intradermal vaccinations 
(Coulman et al., 2006; Edens et al., 2015a; Edens et al., 2015b; Pearton et al., 
2013), causing minimal tissue disruption and no pain or bleeding upon clinical use. 
Recent studies have also started using these devices for intradermal 
administration of a tolerogenic auto-antigen, leading to effective presentation of 
antigen to T cells in skin draining lymph nodes and reduced antigen-specific T cell 
proliferation in the pancreatic lymph node (Zhao et al., 2016). However, there are 
many types of MNs and each has different advantages and disadvantages, 
depending on their form and function (Prausnitz, 2017). Previous studies have dry 
coated a naked peptide auto-antigen onto stainless steel MNs prior to their 
intradermal administration (Zhao et al., 2016). However, the deposition and local 
kinetics of the coated formulation are predominantly dictated by the nature of the 
biological environment and the physicochemical properties of the therapeutic, i.e. 
dissolution of the peptide in the biological milieu. As an alternative, hollow MNs 
provide a clinically approved (Beals et al., 2016; Bragazzi et al., 2016) system that 
uses either single needles or a plurality of microstructures for delivery of a discrete 
volume of a liquid formulation into the intradermal space. The MicronJet600 
device, from NanoPass Technologies Ltd, is a hollow CE-marked MN device for 
clinical use and has stimulated robust immune responses to vaccines (Levin et al., 
2015) at potentially reduced antigen doses. The sterile device is mounted on a 
standard syringe in much the same way as a conventional hypodermic needle, 
allowing for simple and reliable use and disposal.  It has therefore been adopted 
in this study to provide a reproducible minimally invasive conduit into the skin for 
the AuNP self-antigen delivery platform. 
This study describes the pre-clinical investigations that have characterised the 
physicochemical properties of the PIC19-A3 conjugated AuNPs, their physical 
stability upon extrusion through MicronJet600 MNs, the distribution of PIC19-A3 
AuNPs within ex vivo human skin after MN injection, the uptake of PIC19-A3 AuNPs 
by human skin cells and the effect of this uptake on DCs. These studies have been 
crucial to provide our consortium, The Enhanced Epidermal Antigen Specific 
Immunotherapy Against Type 1 Diabetes (EE-ASI) consortium (www.ee-asi.eu), 
with the understanding needed to translate the AuNP platform to the clinic for the 
immune intervention therapy of Type 1 diabetes. 
 
 
 
 
  
2. MATERIAL AND METHODS 
 
All reagents and laboratory consumables were purchased from Fisher Scientific, 
UK unless otherwise indicated. Proinsulin peptide PIC19-A3 (AmbioPharm Inc, North 
Augusta, SC, USA) and GAD339-352 peptide (Innovagen AB, Sweden) were 
synthesised with a thiol linker to enable covalent binding to AuNPs.   
 
2.1. Microneedle devices 
The MN device used in this study (MicronJet600 (MJ600); NanoPass Technologies 
Ltd) consists of 3 pyramid-shaped MNs of 0.6 mm (600 μm) length integrated with 
a plastic hub that can be attached to any standard Luer syringe (Supplementary 
Figure 1). 
 
2.2. AuNP characterization 
AuNPs were synthesized and supplied by Midatech Pharma. Peptide loaded 
AuNPs were manufactured containing three peptide concentrations (3%, 5% and 
10%) and either a glucose or mannose carbohydrate moiety. The identities of the 
formulations used in specific elements of the work are detailed in the relevant 
results and figure legends. Morphological analysis was performed by transmission 
electron microscopy (TEM; JEM-2100 LaB6, JEOL, USA). Samples were applied 
to a grid and dried for approximately 60 s under ambient conditions. Mean particle 
size (hydrodynamic particle size) was determined by dynamic light scattering 
(DLS) using 173° backscatter detection. Electrophoretic mobility was measured by 
Laser Doppler Velocimetry (LDV) and converted to zeta potential (ZP) values using 
the Smoluchowski equation. Both measurements (DLS and LDV) were performed 
on formulations in triplicate, both before and after MN injection, using a Zetasizer 
Nano ZS series Nano-ZS ZEN3600 fitted with a 633 nm laser (Malvern Instruments 
Ltd., UK). Changes to gold concentration following MN injection was assessed by 
UV/vis absorption at 405 nm using a BMG FLUOstar Optima microplate reader. 
 
2.3. Collection, processing and maintenance of ex vivo human skin 
Human skin samples were obtained from female patients aged 38-86 years, 
following mastectomy or breast reduction under informed patient consent and 
ethical approval (South East Wales Local Research Ethics Committee; 
08/WSE03/55). Excised skin was collected immediately after surgery and 
transported at 4°C in media consisting Dulbecco’s modified Eagle medium 
(DMEM; Life Technologies, UK), 100 unit ml-1 penicillin and 100 μg ml-1 
streptomycin (ThermoFisher Scientific Ltd, UK). Subcutaneous adipose tissue was 
removed by blunt dissection and skin was pinned, dermis side down, onto a cork 
dissection board to facilitate MN injection. 
 
2.4. Visualising AuNP distribution within skin sections by microscopy 
AuNPs (blank and conjugated to PIC19-A3) and commercially available 50nm 
colloidal AuNPs (Sigma-Aldrich, UK) were injected (50 μl in PBS) into ex vivo 
human skin via MJ600 MNs. Following injection, 8 mm biopsy punches were 
extracted and placed into fixative (4% v/v formaldehyde / 0.2% glutaraldehyde, pH 
7.3; t = 0 h) or incubated for 4 h at air-liquid interface at 37 °C in an atmosphere of 
5% (v/v) CO2/95% (v/v) air before fixation. Processing for transmission electron 
(TEM) or light microscopy involved bisection along the injection site, post-fixation 
in either 2% aqueous uranyl acetate or 0.2% (w/v) aqueous osmium tetroxide, 
washing in water, dehydration through graded propan-2-ol and embedding in LR 
White acrylic resin (London Resin Company, Reading, U.K.). The resulting resin-
embedded sample was mounted in an ultramicrotome and the block face trimmed 
to a trapezium with a glass knife. For light microscopy, 0.4 μm sections were 
collected onto Vectabond-treated glass slides (Vector Labs, Peterborough, UK) 
and dried at 50°C. For visualization of AuNPs, sections of uranyl-acetate post-fixed 
tissue were incubated directly in Newman and Jasani’s physical developer 
(Newman and Jasani, 1998). Sections of osmium tetroxide post-fixed samples 
were additionally pre-treated for 1 h with saturated sodium periodate before 
incubation in the physical developer. Prepared slides were counterstained with 
Goldner’s Light Green (0.2% w/v Light Green SF in 0.2% v/v acetic acid) and 
visualized with an Olympus BX 51 research light microscope fitted with a Zeiss 
Axiocam digital camera. For TEM, 100 nm sections were collected onto EM grids, 
stained with uranyl acetate and lead citrate, and examined in the CM12 TEM (FEI 
(UK Ltd), UK). 
 
2.5. Human cells 
2.5.1. HaCaT cell culture. Immortalized human keratinocyte cells, HaCaT 
cells(Boukamp et al., 1988), were received as a gift from Professor Mark 
Gumbleton (School of Pharmacy and Pharmaceutical Sciences, Cardiff 
University). Cells were cultured in growth medium (DMEM supplemented with 10% 
v/v fetal bovine serum (FBS; VWR International, UK), 100 unit ml-1 penicillin and 
100 μg ml-1 streptomycin) at 37°C in a humidified atmosphere containing 5% v/v 
CO2.   
 
2.5.2. Isolation and culture of primary keratinocytes. A superficial layer of the 
skin (collected and prepared as described in section 2.3) was separated using a 
surgical blade and transferred into a centrifuge tube containing 0.25% (w/v) trypsin 
solution and stored overnight at 4°C. Suspended cells were filtered through a 70 
μm cell strainer and centrifuged at 300 x g for 7 min. The cell pellet was gently re-
suspended in media containing EpiLife medium (Life Technologies, UK) 
supplemented with 10% human keratinocyte growth supplement (Life 
Technologies, UK), 100 unit ml-1 penicillin, 100 μg ml-1 streptomycin and 2.5 μg ml-
1 amphotericin B (VWR International, UK) and seeded in a 25 cm3 flask. The media 
was changed every 2-3 days until primary cells reached 70-80% confluency.  
 
2.5.3. Fresh isolation of human skin cell suspensions. After collection and 
preparation of the skin sample as described in section 2.3 the bulk of lower dermis 
was removed by blunt dissection. The remaining tissue containing epidermis and 
upper dermis was cut into small pieces and immersed in enzyme cocktail solution 
containing Dispase II (2 units ml-1), Collagenase I (197 units ml-1) and 
Deoxyribonuclease I (DNA-se I) from bovine pancreas (20 units ml-1) in Roswell 
Park Memorial Institute (RPMI) 1640 media (Sigma-Aldrich, UK) for 1 h at 37°C. 
Following incubation, epidermal sheets were mechanically separated and 
transferred into 0.25% (w/v) trypsin solution in PBS for 30 min at 37°C (Boyce and 
Ham, 1983). After incubation, soybean trypsin inhibitor (1 mg ml-1) was added and 
the epidermal cell suspension was filtered through a 70 μm cell strainer, 
centrifuged at 400 x g for 10 min and re-suspended in the appropriate solution 
depending on the experimental procedure. Dermal cells were isolated using a 
‘walkout’ protocol. Separated dermis was placed in RPMI media supplemented 
with 10% (w/v) human AB serum, 100 unit ml-1 penicillin, 100 μg ml-1 streptomycin 
and 2.5 μg ml-1 amphotericin B and incubated at 37°C for 48 h. Dermal cells 
present in the media were filtered through a 70 μm cell strainer, centrifuged at 400 
x g for 10 min and re-suspended in the appropriate solution depending on the 
experimental procedure. 
 
2.5.4. In vitro generation of human dendritic cells (DCs). Monocyte-derived 
dendritic cells (moDC) were generated as previously described (Kleijwegt et al., 
2010). In short, peripheral blood mononuclear cells (PBMCs) were isolated from 
buffy coats of healthy donors and monocytes were purified by CD14-specific 
positive magnetic cell sorting according to the supplier’s protocol (MACS, Miltenyi 
Biotec, Germany). Isolated monocytes (~90% pure) were cultured in RPMI 1640 
medium supplemented with antibiotics and 10% heat-inactivated fetal calf serum 
(FCS, Greiner, Wemmel, Belgium). DC differentiation was induced using 
recombinant human IL-4 (500 U ml-1, Invitrogen, The Netherlands) and 
recombinant human GM-CSF (800 U ml-1, Invitrogen). Medium and cytokines were 
refreshed on day 3. On day 6, immature moDCs were harvested and 
cryopreserved until subsequent stimulation.  
 
2.6. Cellular uptake of FITC-labelled AUNPs 
AuNPs were conjugated to a FITC-labelled peptide and this construct was used to 
determine cell uptake. The small distance between conjugated FITC-labelled 
peptide molecules and the gold quenches the fluorescence (Loumaigne et al., 
2010). However, once the peptide is cleaved from the AuNP the FITC fluorescence 
can be detected by fluorescent microscopy or flow-cytometry. This occurs 
intracellularly and therefore is a marker of cellular uptake and 
cleavage/processing. 
 
2.6.1. Cellular uptake of FITC-labelled AuNPs in human keratinocyte cell 
lines. Twenty-four hours before treatment, HaCaT (passage 77-86) or primary 
keratinocyte (passage 6-10) cells were seeded into 24-well plates at a density of 
1x105 per well in 0.5 ml of growth medium. Cell populations were then washed with 
PBS and treated with 0.5 ml of various FITC-labelled AuNP formulations at 10 μg 
ml-1 (with respect to gold concentration) in serum-free media (DMEM, 100 unit ml-
1 penicillin and 100 μg ml-1 streptomycin). Serum-free media was used as a control. 
Following 30 min, 4 h, 24 h, 48 h or 72 h incubation AuNPs were removed, cells 
were washed twice with PBS and trypsinised at 37°C for 10 min with trypsin-EDTA. 
Cells were then re-suspended in growth medium, centrifuged at 300 × g for 5 min 
and washed with PBS. Pelleted cells were fixed with 100 μL fixation buffer (BD 
Biosciences, UK) for 15 min at 4°C, washed and re-suspended in 200 μl of stain 
buffer (BSA), (BD Biosciences, UK) before flow cytometry analysis (FACSVerseTM, 
BD Biosciences, UK) using a 3-laser, 8-color (4-2-2) configuration. 
 
For confocal microscopy HaCaT or primary keratinocyte cells were seeded in glass 
bottom dishes (MatTek Corporation, USA) at a density of 3x105 per well in 1.5 ml 
of growth media. Cell populations were then washed with PBS and treated with 1.5 
ml of various types of AuNPs prepared at concentration of 10 μg ml-1 (with respect 
to gold) in serum-free media. Serum-free media was used as a control. Following 
30 min, 4 h and 24 h of incubation the nanoparticle suspension was removed from 
the cell surface and cells were washed twice with PBS before the addition of 
EpiLife imaging media to conduct imaging studies using a DMI 6000 Leica confocal 
microscope equipped with 350, blue diode 405, Argon 488 and HeNe 543 and 
633nm lasers. 
 
2.6.2. Cellular uptake of FITC-labelled AuNPs in mixed cell suspensions from 
human skin. Mixed cell suspensions of epidermal/dermal cells were isolated as 
described in section 2.5.3. Cells were further counted and placed in 96-well round 
bottom plate (Corning Costar, UK) at cell densities of 1x105 per well in 100 μl of 
RPMI serum-free media. Fluorescently labelled AuNPs were prepared in RPMI 
serum-free media at 20 μg ml-1 (with respect to gold) and 100 μl of prepared 
formulation were added to each well (final AuNP concentration 10 μg ml-1). 
Following incubation at 37°C in a humidified atmosphere containing 5% v/v CO2, 
the cells were pelleted by centrifugation at 400 × g for 10 min and washed with 
PBS. Pelleted cells were fixed with 100 μl fixation buffer for 15 min at 4 °C, washed 
and re-suspended in 200 μl stain buffer (BSA), (BD Biosciences, UK) before flow 
cytometry analysis.  
 
For confocal microscopy a single cell suspension of epidermal/dermal cells was 
exposed to fluorescently labelled AuNPs as described in section 2.6.1. Following 
incubation with AuNPs, cells were washed in PBS, pelleted by centrifugation at 
400 × g for 10 min, re-suspended in 100 μL of EpiLife media and placed in glass 
bottom dishes for live cell imaging. 
 
2.6.3. Extracting cells from excised human skin, previously injected with 
FITC-labelled AuNPs, to determine cellular uptake ex vivo. Fresh human skin 
was obtained and processed as described in section 2.5.3. Following tissue 
preparation, the skin was pinned, dermis side down, onto a cork dissection board 
and 50 μl of FITC-labelled AuNPs or PBS (as control) were injected using the 
MJ600 device. Thereafter 8 mm biopsy punches were incubated for 4 or 24 h at 
the air-liquid interface at 37°C and 5% v/v CO2. Injections were performed in at 
least triplicate. Biopsy punches were subsequently processed by enzymatic 
separation of epidermis from dermis as described in the section 2.5.3. Isolated skin 
cells were washed in PBS and prepared for either flow cytometry or confocal 
microscopy as described in the previous section. 
 
2.6.4. Immunostaining cells extracted from excised human skin injected with 
FITC-labelled AuNPs. Single cell suspensions from untreated and treated (FITC-
labelled PIC19-A3 AuNP) skin explants were prepared as described in the section 
2.5.3. The cells were centrifuged at 400 × g for 10 min and re-suspended in the 
relevant antibodies in stain buffer (BSA), (BD Biosciences, UK). Epidermal cells 
were stained with V450 mouse anti-human HLA-DR (dilution 1:50, BD 
Biosciences, UK) and PE anti-human CD207 (dilution 1:50, BioLegend, UK), while 
dermal cells were stained with V450 mouse anti-human HLA-DR (dilution 1:50, BD 
Biosciences, UK) and CD11c human APC (dilution 1:20, Miltenyi Biotec Ltd., UK). 
Mixtures were incubated for 1 h in the dark at 4°C and the staining process used 
a 100 μl staining media with 1x105 cells/test. Simultaneously, for compensation 
purposes, the appropriate species matching compensation beads (Anti-Mouse Ig, 
κ/Negative Control Compensation Particles Set, BD Biosciences, UK) were 
incubated separately with each dye under the same conditions. After incubation, 
cells were centrifuged at 400 x g, washed and re-suspended in 200 μl of stain 
buffer (BSA) before flow cytometry. Filters that were used include SSC (488/15), 
FITC (527/32), PE (586/42), APC (660/10) and V450 (448/45). 
 
2.6.5. Cellular uptake of FITC-labelled AuNPs in human moDCs. Immature 
DCs were incubated with FITC-labelled AuNPs for 4 h to allow uptake, after which 
free AuNPs were washed away by centrifugation. The DCs were subsequently 
cultured overnight in standard growth medium or 100 ng ml-1 LPS (Sigma Aldrich 
Chemie, The Netherlands) where indicated. Staining of moDCs was analysed by 
flow cytometry (FACS CaliburTM, BD Biosciences, UK).  
 
2.7. In vitro T cell stimulation by human moDCs treated with FITC-labelled 
AuNPs 
T cell stimulatory capacity of control or AuNP-treated DCs was tested using either 
an effector T cell clone specific for GAD65 peptide (GAD339-352)(Schloot et al., 
1999) or allogeneic CD4+ T cells, which were isolated from PBMCs using a 
negative selection kit (Dynal, Invitrogen, The Netherlands). CD4+ T cells were 
plated at 105 T cells per well with different ratios of DCs and cultured in IMDM 
(Dulbecco) supplemented with 10% human serum. Four days later, cell cultures 
were pulsed overnight with [3H]-thymidine and incorporation was determined.  
 
2.8. Data processing 
Flow cytometry data were analysed using FlowJo Flow Cytometry Analysis 
Software for Mac Version 10.0 (Tree Star Inc., USA). Image processing including 
scale bar inclusion was performed using ImageJ software (National Institute of 
Health, USA). 
 
 
3. RESULTS AND DISCUSSION 
 
The intradermal delivery of an auto-antigen loaded AuNP using a minimally 
invasive MN delivery system to enhance autoantigen uptake into, and promote 
tolerance from, relevant APCs combines technologies and knowledge from the 
pharmaceutical sciences and immunology to provide a potential treatment for the 
improvement of antigen-specific immunotherapy for T1D. Development, 
characterisation and incremental optimisation of the system is fundamental to 
clinical translation and success. 
Initial studies ensured that AuNP-peptide complexes could be manufactured and 
tuned to ensure physical stability upon extrusion through MNs. AuNPs used in this 
study comprise a core of gold atoms to which an organic layer of carbohydrates 
(glucose (G) or mannose (M)), glutathione (GSH) and proinsulin peptide (PIC19-A3) 
were attached, via sulphur bonds (Figure 1A). GSH enables non-enzymatic 
intracellular activation / release of prodrugs (Sies, 1999), based on the difference 
in intracellular GSH concentration (1-10 mM) relative to extracellular thiol levels (2 
μM glutathione, 8 μM cysteine) (Jones et al., 1998) and provides a negative 
surface charge that could potentially be used for electrostatic loading of further 
elements. The carbohydrate moiety was included to enhance solubility of the 
constructs and has previously been shown to heighten uptake of NPs (Kang et al., 
2015; Rana et al., 2012), including gold nanoclusters (<3nm) (Fernandez et al., 
2015), by monocyte derived DCs (MoDCs). The amount of each ligand utilised in 
the AuNP corona synthesis reaction is expressed in terms of relative percentage 
by weight, for example AuNP synthesised with 3% peptide and 5% glucose would 
also contain 92% GSH by weight. Transmission electron microscopy (TEM) 
indicated that suspensions of the AuNP-peptide complexes were relatively 
homogenous with a nanoparticle diameter of 2-4nm, irrespective of the peptide 
concentration (1%, 3% and 10%) or sugar moiety used in the formulation (G or M) 
(Figure 1B-D). Dynamic laser scattering data generally supported TEM 
observations and, importantly, injection through MicronJet600 MNs (MJ600) did 
not change the diameter of AuNPs (Figure 1E). UV/Vis absorbance measurements 
confirmed no loss of AuNPs following their injection through MJ600 MNs (Figure 
1F) and complexes containing both 1% and 3% peptide remained negatively 
charged (-40mV to -60mV) following their extrusion through the micron-sized MN 
bore (Figure 1E). These data sets indicate that the AuNP colloidal formulation is 
physically stable to the shear forces that are created upon injection and does not 
irreversibly interact with the MJ600 materials. However, the zeta potential 
distribution profiles of AuNPs formulated with 10% peptide were notably altered 
following MN extrusion (Supplementary Figure 2), which indicates physical 
instability of the formulation at the higher PIC19-A3 doses and a maximum loading 
capacity of 5-10% for the selected AuNPs. Subsequent studies therefore adopted 
a AuNP formulation containing 3% peptide and the volume of formulation was 
tailored to achieve the anticipated therapeutic dose (10µg) of PIC19-A3 (Thrower et 
al., 2009). 
 
In order to promote a regulatory response to the PIC19-A3 autoantigen we employed 
the CE-marked MJ600 device to target skin DCs whilst minimising the trauma of 
intradermal delivery and any ensuing cutaneous inflammation (Mutyambizi et al., 
2009). The device has three hollow silicon MNs of 600μm length and has been 
used extensively in clinical studies to deliver a range of macromolecular 
formulations including insulin (Kochba et al., 2016), varicella zoster (Beals et al., 
2016), polio (Anand et al., 2015; Troy et al., 2015) and seasonal and pandemic 
influenza vaccines (Della Cioppa et al., 2014; Hung et al., 2012a; Hung et al., 
2012b; Levin et al., 2014; Levin et al., 2016; Van Damme et al., 2009). However, 
whilst there are a number of publications showing successful therapeutic readouts 
upon use of hollow MNs, there is a paucity of information related to the behaviour 
of injected materials in the local environment and how formulation or 
physicochemical drug properties influence distribution and retention in situ 
(Mansoor et al., 2015). Local kinetics and the interactions of the PIC19-A3 AuNP 
construct with the cellular and extracellular environment in the skin will be key to 
the potential therapeutic effects. A silver staining technique was therefore used to 
visualise tissue distribution of AuNPs (initially placebo AuNPs without auto-
antigen) in the skin following MJ600 MN injection. AuNPs were detectable in both 
the viable epidermis (Figure 2B, C) and the dermis. Repeat studies using AuNP 
complexes covalently linked to PIC19-A3 supported these initial observations, 
illustrating that after just four hours the PIC19-A3 AuNP complex had diffused 
extensively from the injection site throughout the papillary and reticular dermis, 
with accumulation at the basement membrane zone and in cells of the viable 
epidermis (Figure 2E). These results contrasted with parallel studies that used 
larger colloidal AuNPs (50 nm diameter) as control (Figure 2F) and previously 
published studies using polystyrene NPs (50-100nm diameter) (Coulman et al., 
2009; McAllister et al., 2003), whereby MN delivered NPs were retained in the 
dermis in close association with collagen and elastin fibres. Within the intradermal 
space the ultra-small AuNPs therefore behave more like a solution than the more 
conventional colloidal formulation of larger NPs (Labouta et al., 2011). Their 
greater diffusive properties (Fernandez et al., 2015; Kohli and Alpar, 2004; 
Sonavane et al., 2008) enable the AuNP-peptide complex to reflux from the point 
of dermal deposition, across the tightly packed basement membrane and into the 
viable epidermis of human skin. This is potentially advantageous as the epidermis 
is the most cellular region of the tissue and contains a vast network of epidermal 
Langerhans cells, which are key mediators in tolerisation mechanisms (Deckers et 
al., 2018). 
 
TEM enabled closer scrutiny of the distribution of PIC19-A3 loaded AuNPs in human 
skin at the cellular level. Following MJ600 delivery AuNPs were co-localised within 
cells that had phenotypic characteristics indicative of keratinocytes (Figure 3A), 
epidermal dendritic cells, i.e. LCs with signature Birbeck granules (Figure 3B) and 
dermal cells (Figure 3C). These observations were supported by in vitro studies in 
immortalised keratinocytes, primary keratinocytes and freshly isolated human skin 
cells, all of which demonstrated efficient uptake of FITC-labelled PIC19-A3 AuNPs 
following topical application (Supplementary Video 1; Supplementary Figure 3). 
Whilst cultured cell lines (HaCaT cells and primary keratinocytes) required a 
contact time between 30min and 4 h for cell uptake, cells that were freshly 
extracted from human skin were able to internalise the AuNP complex after a 
contact time of just 30 min (Supplementary Figure 3a). This indicates that a 
delivery method which is able to facilitate direct contact between skin cells and the 
AuNP complex in vivo, is likely to facilitate rapid cell uptake.  
 
Studies progressed to further examine and quantify cell uptake of the AuNPs in 
situ. Following MJ600 delivery of PIC19-A3 AuNPs into freshly excised human skin 
tissue, cells were subsequently extracted and analysed by flow cytometry. 
Immunostaining of these cells identified HLA-DR+/CD207+ (epidermal LCs) 
(Figure 4A) and HLA-DR+/CD11c+ (dermal DCs) (Figure 4B) cells within the total 
extracted epidermal and dermal cell populations respectively. After 4 h, 94% of the 
extracted LCs and 29% of the dermal DCs were FITC positive, compared to 34% 
and 46% of the other epidermal and dermal cells respectively (Figure 4C). 
Confocal microscopy confirms that the PIC19-A3 AuNPs associated with these cells 
are internalised, rather than binding to the exterior of the cell membrane, with 
AuNPs visualised throughout the cell cytoplasm (Figure 5, Supplementary Video 
1). 
This data indicates preferential internalisation of the PIC19-A3 AuNP complex by 
epidermal LCs in situ. Whilst the differences in the isolation techniques for the 
epidermal and dermal cells may contribute to this disparity between LCs and 
dermal DCs (dermal DCs are isolated from skin using a walk out method, whereas 
LCs are isolated by enzymatic digestion of the epidermis), in vitro data 
(Supplementary Figure 3) also indicates that epidermal cells internalise the AuNP 
complex more efficiently than dermal cells. This supports the notion of preferential 
uptake of the AuNP construct by epidermal LCs. Enhanced uptake may be 
attributed to a greater contact area between the formulation and LCs as a result of 
their extensive network of dendrites that probe across multiple cellular layers of 
the viable epidermis, the mobility of LCs within the excised human tissue, the 
greater propensity of these APCs to internalise foreign materials or a combination 
of these factors (Deckers et al., 2018).  
 
LCs are constantly sampling the local environment and migrating to lymph nodes 
to present antigens. In the non-activated state, LCs present self-antigens and this 
is thought to be key to tolerance mechanisms and homeostasis. However, upon 
injury, infection or inflammation LCs are stimulated to help orchestrate a 
pathogenic immune response. Therefore whilst successful delivery of the PIC19-A3 
AuNPs to the relevant APCs is a key pre-cursor to our tolerogenic strategy,  it must 
be followed by cellular presentation of the peptide to naïve T cells that 
subsequently adopt a regulatory rather than inflammatory phenotype (Banchereau 
and Steinman, 1998). moDCs provide an APC laboratory model that whilst not 
identical to those LCs found in skin, can be used to probe biological effects due to 
their comparable phenotype and functionality. Much like those previous studies 
conducted with skin derived LCs and DCs, internalisation of the fluorescent PIC19-
A3 AuNP complex by moDCs was both rapid and highly efficient (Figure 6A, B). 
 
Investigating the interactions of AuNP-peptide treated MoDCs with T cells requires 
a T cell clone that is specific to the peptide. These clones were not available for 
PIC19-A3 and so the GAD65 peptide (GAD339-352) was used as a relevant 
autoantigen model, for which we had a GAD339-352-specific memory T cell clone. 
To dissociate the influence of AuNPs on T cell stimulation from antigen uptake and 
processing, moDCs were incubated with AuNPs not coupled to an antigen (blank 
AuNPs) for 4 hours, at various concentrations (corresponding to 0.03, 0.3 and 3 
µg/ml of gold), which were subsequently washed and incubated with either naïve 
allogeneic CD4+ T cells (Figure 7A) or a GAD339-352-specific T cell clone in the 
presence of soluble GAD339-352 peptide (Figure 7B). AuNPs reduced the capacity 
of DCs to stimulate proliferation of naive allo-reactive T cells in a dose dependent 
manner with respect to gold (Figure 7A), whilst a similar effect on GAD-specific 
memory T-cells was not apparent (Figure 7B). This suggests that AuNPs have a 
suppressive effect with respect to the presentation of a peptide to naïve T cells, 
which therefore prevents subsequent priming and activation. These findings agree 
with data showing that AuNPs, particularly smaller ones (10nm vs 50 nm), impair 
LPS-induced maturation and allo-stimulatory capacity of DCs(Tomic et al., 2014). 
This effect was not evident with memory T-cells, which may be explained by the 
fact that CD4 memory T-cells require less co-stimulation for activation in 
comparison to CD4+ naïve T cells. The impaired maturation of DCs may be 
valuable in promoting tolerance to antigen attached to AuNPs, for example in the 
treatment of autoimmunity, as immature DCs promote the generation of regulatory 
T cells(Suwandi et al., 2017). 
To analyse the kinetics of antigen processing and presentation provided by the 
AuNP complexes, moDCs were pulsed with AuNPs coupled to GAD339-352 peptide 
and incubated for 24-72 hours before used in a co-culture with the GAD-specific 
memory clone. Prolonged incubation of moDCs with AuNP GAD339-352 complexes 
enhanced proliferation of GAD-specific effector T-cells compared to control 
moDCs that had been pulsed with soluble GAD339-352 peptide alone (Figure 7C). 
This indicates that the peptide payload on AuNPs can be taken up, processed and 
presented efficiently by DCs to T cells, more efficiently than a soluble peptide, 
though in the context of this experiment the interaction was designed to give a 
stimulatory, rather than regulatory, effect.  
 
4. CONCLUSIONS 
This study has demonstrated and characterised localised delivery of self-peptide 
conjugated AuNPs into human skin via MicronJet600 hollow MNs. Adopting this 
delivery strategy supports three important pre-requisites for successful tolerance 
induction through antigen specific immunotherapy, i.e. delivery (1) to the right 
tissue – the APC-rich epidermal layer of skin (2) to the right cells - predominantly 
LCs, and (3) in the right way - minimally invasive delivery with reduced DC 
activation (i.e. DCs remain in the immature state). Clinical studies are underway to 
determine if this system can indeed act as a platform for antigen specific tolerance 
induction. 
 
5. FIGURES 
Figure 1. A) Composition of AuNPs conjugated with PIC19-A3 peptide, glutathione and either glucose 
(G) or mannose (M). B-D) TEM images of PIC19-A3-AuNP complexes formulated with 5% glucose 
and different concentrations of the C19-A3 peptide (1% (B), 3% (C) or 10% (D). E, F) Stability of 
AuNP formulations both before and after injection through MicronJet600 MNs as measured by 
changes in E) particle size (nm) and zeta potential (mV) and F) gold concentration, as measured 
by UV/Vis absorbance. 
 
Figure 2. Light microscopy images of control (A, D) and AuNPs injected (B, C, E, F) into fresh 
human skin using 600µm MicronJet MNs. Tissue biopsies were fixed at t=0h and t=4h and analysed 
for AuNP distribution. B, C) AuNPs formulated with 90%glutahthione/10%glucose were injected at 
concentration of 20 µg/ml (with respect to gold) and E) AuNPs containing 3% PIC19-A3 peptide and 
5%glucose were injected at concentration of 338 µg/ml (with respect to gold). F) Distribution of 
control 50nm AuNPs. SC = stratum corneum, E = epidermis, D = dermis. 
 
Figure 3. TEM images of epidermal (A, B) and dermal cells (C) following injection of AuNPs 
(90%glutathione/10%glucose) (A) or a AuNP complex formulated with 1% of PIC19-A3 peptide (B, C) 
using 600µm MicronJet MNs. 
 
Figure 4. Flow cytometry of skin cells isolated from human skin 4 h after MJ600 injection of 
fluorescent 3%PIC19-A3 AuNPs (corresponding to 300 μg/ml to gold). (A) Representative example of 
uptake by epidermal skin cells (expressed as MFI); (B) Representative example of uptake by 
dermal skins cells (expressed as MFI); (C) Percentage of FITC+ cells before (circles) and 4 h after 
(squares) FITC-labelled PIC19-A3 AuNP injection into the human skin explants (n=4), note: uptake of 
HLA-DR+, CD11c- population was low i.e. <10% (data not shown). eDCs – epidermal DCs HLA-
DR+, CD207+; other epidermal cells - HLA-DR-, CD207-; dDCs - dermal DCs HLA-DR+, CD11c+; 
other dermal cells HLA-DR-, CD11c-; solid grey – untreated; black line - after 4 h. 
 
Figure 5. Internalisation of FITC-labelled PIC19-A3 AuNPs into epidermal (A) and dermal (B) cells, 
isolated from skin explants, was confirmed using confocal microscopy. Injection concentration was 
444 µg/ml (with respect to gold) corresponding to 10 µg of PIC19-A3 in 50 µl water. Cells were stained 
with Hoescht (blue, nuclear staining), cell mask (red), FITC-labelled peptide (green). 
 
Figure 6. Immature moDCs were incubated with PIC19A3 AuNPs (formulated with 3% peptide, 5% 
glucose). Fluorescence from released peptide was detected at 4 h using microscopy (A) and 
quantified using flow cytometry (B). Solid light grey – baseline; solid dark grey – after 4 h; dashed 
line - unstained. 
 Figure 7. Immature moDCs were incubated with AuNPs (no antigen, 5% glucose) at different 
concentrations (with respect to gold) for 4 h, and subsequently co-cultured with polyclonal naïve 
CD4+ T cells (A) or GAD339-352-specific memory T cells in the presence of 5μg/ml soluble GAD339-
352 peptide (B). Proliferation (3H–thymidine incorporation) was measured after 3-days of co-culture. 
(A) AuNPs reduced the capacity of DCs to stimulate proliferation of naive alloreactive T cells. (B) 
AuNPs did not reduce the capacity of DCs to stimulate a GAD-specific T cell clone. (C) Immature 
moDCs were treated for 4h with soluble GAD339-352 peptide (5μg/ml) or with AuNPs (3% GAD339-352, 
5% glucose, 27.5μg/ml gold) at a concentration corresponding to 5μg/ml GAD-peptide, and 
subsequently incubated with LPS (100ng/ml) for 24, 48 or 72 h. Thereafter DCs were collected, 
remaining free peptide or AuNPs was removed and DCs were co-cultured with GAD339-352-specific 
memory T cells. Empty squares depict proliferation (3H–thymidine incorporation) of the GAD-clone 
when stimulated with soluble-peptide pulsed moDC. Dark squares depict proliferation when 
stimulated with AuNPs (loaded with peptide) pulsed moDC. Data show a representative of three 
independent moDC donors and was performed in triplicate. 
 
Supplementary Figure 1.	A) The NanoPass MicronJet600 device, consisting of three MNs, each 
600μm in length and B) electron microscopy of a single NanoPass MN (enlarged by x330). 
 
Supplementary Figure 2. Zeta potential distribution profiles of AuNP formulated with 1% of PIC19-A3 
peptide (A, B) or 10% of PIC19-A3 peptide (C, D) before (A, C) and after (B, D) injection through 
600µm MicronJet MNs. 
 
Supplementary Figure 3. A) Flow cytometry data on cellular uptake of FITC-labelled AuNPs 
containing 3% PIC19A3, 5%G in cultured HaCaT cells, primary human keratinocytes or in epidermal 
and dermal cells freshly isolated from human skin. B, C, D, E) Confocal microscopy images of the 
internalization of 3% PIC19A3 FITC-labelled AuNPs into HaCaTs (B), primary keratinocytes (C), 
epidermal (D) and dermal (E) cells isolated from excised human skin. Cells were stained with 
Hoescht (blue, nuclear staining), cell mask (red in B, C) and dendritic cell marker CD11c (red in E). 
FITC-labelled peptide is indicated in green.  
 
 
Supplementary Movie 1. Internalisation of FITC-labelled PIC19-A3 AuNPs into primary keratinocytes 
following 4 h incubation with 3%PIC19-A3 5%G. Cells were stained with Hoescht (blue, nuclear 
staining), cell mask (red), FITC-labelled peptide (green). 
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